DRTS net incomeFY2025-$42.63M
DRTS net income was -$42.63M for fiscal 2025 (ended Dec 31, 2025), compared with -$31.75M in fiscal 2024.
Alpha Tau Medical Ltd. (DRTS) financials
For fiscal 2025 (ended Dec 31, 2025), Alpha Tau Medical Ltd. reported -$42.63M of net income.
- Net income, FY2025
- -$42.63M
- Free cash flow, FY2025
- -$32.76M
- EPS, diluted, FY2025
- -$0.53
- Cash
- $12.20M
- Market cap
- $1.30B
FY2019FY2025
FY2019FY2025
DRTS revenue and earnings growth
DRTS EPSFY2025-$0.53
DRTS diluted EPS was -$0.53 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.45 in fiscal 2024.
DRTS free cash flowFY2025-$32.76M
DRTS free cash flow was -$32.76M for fiscal 2025 (ended Dec 31, 2025), compared with -$22.02M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $32.06M | $27.02M | $26.42M | $20.89M | $11.45M | $7.54M | $6.64M |
| Selling, general and admin | $8.36M | $6.67M | $7.33M | $10.27M | $1.86M | $1.41M | $977.0K |
| Operating income | -$42.29M | -$36.04M | -$35.68M | -$32.14M | -$13.79M | -$9.24M | $8.01M |
| Interest expense | $347.0K | $303.0K | $75.0K | - | - | - | - |
| Pre-tax income | -$42.51M | -$31.74M | -$29.14M | -$33.74M | -$27.26M | -$8.72M | $8.32M |
| Income tax | $121.0K | $6.0K | $16.0K | $20.0K | $7.0K | $158.0K | -$146.0K |
| Net income | -$42.63M | -$31.75M | -$29.16M | -$33.76M | -$27.27M | -$8.88M | -$8.37M |
| EPS, basic | -$0.53 | -$0.45 | -$0.42 | -$0.53 | -$0.67 | -$0.22 | -$0.25 |
| EPS, diluted | -$0.53 | -$0.45 | -$0.42 | -$0.53 | -$0.67 | -$0.22 | -$0.25 |
| Diluted shares | 80.6M | 69.9M | 69.4M | 63.5M | 40.5M | 40.3M | 33.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $12.20M | $13.72M | $12.66M | $6.69M | $23.85M | $16.17M | $1.84M |
| Short-term investments | $60.92M | $45.88M | $69.13M | $98.69M | $8.08M | - | - |
| Current assets | $78.30M | $64.23M | $85.76M | $106.48M | $32.64M | $47.45M | - |
| Total assets | $105.65M | $86.20M | $107.39M | $120.15M | $42.22M | $52.99M | - |
| Current liabilities | $10.51M | $8.68M | $7.10M | $4.34M | $4.41M | $2.09M | - |
| Total liabilities | $28.55M | $23.54M | $22.91M | $14.49M | $23.03M | $7.45M | - |
| Shareholders' equity | $77.10M | $62.67M | $84.47M | $105.66M | -$34.78M | -$8.43M | -$193.0K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.68M | -$19.78M | -$17.96M | -$23.88M | -$11.81M | -$7.25M | -$6.91M |
| Capital expenditures | $6.08M | $2.24M | $6.40M | $904.0K | $2.93M | $3.77M | $1.29M |
| Free cash flow | -$32.76M | -$22.02M | -$24.36M | -$24.78M | -$14.74M | -$11.02M | -$8.20M |
| Investing cash flow | -$20.59M | $20.77M | $18.68M | -$89.94M | $19.27M | -$7.82M | -$10.16M |
| Financing cash flow | $45.77M | $25.0K | $5.30M | $96.91M | $111.0K | $29.32M | $5.32M |
| Stock-based compensation | $10.62M | $9.92M | $7.93M | $6.75M | $812.0K | $596.0K | $546.0K |
Key ratios
Source: XBRL data Alpha Tau Medical Ltd. files with the SEC, latest filing dated Mar 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
DRTS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DRTS | - | - | -$42.63M | - | $1.30B |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |
DRTS FAQ
6 questionsIs DRTS profitable?
No. Alpha Tau Medical Ltd. reported a net loss of $42.63M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does DRTS have?
Alpha Tau Medical Ltd. reported $12.20M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is DRTS free cash flow?
Alpha Tau Medical Ltd. generated -$32.76M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$26.68M less capital expenditures.What is DRTS earnings per share?
Diluted earnings per share were -$0.53 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did DRTS last report financial results?
The latest statements here come from Alpha Tau Medical Ltd.'s 20-F filed on Mar 9, 2026, covering the period ended Dec 31, 2025.Where does this DRTS financial data come from?
Quantisnow builds these statements from the structured XBRL data Alpha Tau Medical Ltd. files with the SEC. It is provided for information only and is not investment advice.